Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-25
2008-10-14
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S262100, C514S234200, C514S303000, C514S249000, C544S262000, C544S118000, C544S003000, C544S350000, C546S119000
Reexamination Certificate
active
07435731
ABSTRACT:
Compounds of the formula Ia or Ib:wherein A, B, X, Y, Z, W, k, R1, R2, R3, R4and R5are those defined herein, and compositions comprising the same. The present invention also provides methods for preparing compounds of formula I and using the same in treating p38 mediated disorders in a subject.
REFERENCES:
patent: 3821382 (1974-06-01), Hoyle et al.
patent: 4020072 (1977-04-01), Hoehn
patent: 2003/0207900 (2003-11-01), Chen et al.
patent: 2004/0176325 (2004-09-01), Munson et al.
patent: 2004/0180896 (2004-09-01), Munson et al.
patent: 2005/0277655 (2005-12-01), Ding et al.
patent: 2052719 (1971-09-01), None
patent: 0 104 522 (1991-05-01), None
patent: 1 148 054 (2001-10-01), None
patent: WO 98/09961 (1998-03-01), None
patent: WO 99/23077 (1999-05-01), None
patent: WO 00/27627 (2000-05-01), None
patent: WO 01/98301 (2001-12-01), None
patent: WO 02/22586 (2002-03-01), None
patent: WO 02/051837 (2002-07-01), None
patent: WO 02/059088 (2002-08-01), None
patent: WO 03/000187 (2003-01-01), None
patent: WO 03/009852 (2003-02-01), None
patent: WO 03/029209 (2003-04-01), None
patent: WO 03/062392 (2003-07-01), None
patent: WO 03/068754 (2003-08-01), None
patent: WO 03/099820 (2003-12-01), None
patent: WO 2005085248 (2005-09-01), None
Fijen (Clinical & Experimental Immunology, 2001, 124, 16-20).
Gong et. al. (Chinese Chemical Letters, 2002, 13(7), 613-616).
Hashimoto (J Pharmacol Exp Ther., 2000, 293(2), 370-375).
Esper et. al. (Expert. Opin. Investig. Drugs, 2005, 14(5), 633-645).
Jones et al, “British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.” Gut 2000, (Suppl II)47:ii1-ii19.
Fijen (Clinical & Experimental Immunology, 2001, 124, 16-20).
Gong et. al. (Chinese Chemical Letters, 2002, 13(7), 613-616).
Hashimoto (J Pharmacol Exp Ther., 2000, 293(2), 370-375).
Esper et. al. (Expert. Opin. Investig. Drugs, 2005, 14(5), 633-645).
Badger, A. M., et al. “Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin shock and Immune Function,”J. Pharm. Exp. Therap.(1996) vol. 279 (1) pp. 1453-1461.
Badger, A. M., et al, “SB 203580 Inhibitors p38 Mitogen-Activated Protein Kinase, Nitric Oxide Production, and Inducible Nitric Oxide Synthase in Bovine Cartilage-Derived Chondrocytes,”J. Immunol.(1998) vol. 161, pp. 467-473.
Badger, A. M., et al. “Disease-Modifying Activity of SB242235, A Selective Inhibitor of p38 Mitogen-Activated Protein Kinase, in Rat Adjuvant-induced Arthritis,”Arthritis&Rheumatism(2000) vol. 43, (1) pp. 175-183.
Jackson, J.R. et al., “Pharmacological Effects of SB 220025, a Selective Inhibitor of P38 Mitogen-Activated Protein Kinase, in Angiogenesis and Chronic Inflammatory Disease Models,”J. Pharma. Exp. Therap.(1998) vol. 284, (2) pp. 687-692.
Parasrampuria, D. A., et al., “Single-Dose Pharmocokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen-Activated Protein Kinase Inhibitors: A First-in-Human Study,”J. Clin. Pharmacol.(2003) vol. 43, pp. 406-413.
Pargellis, C. et al., “Inhibitors of p38 Mitogen-Activated Protein Kinase for the Treatment of Rheumatoid Arthritis,”Current Opin. Investigational Drugs(2003) vol. 4 (5) pp. 566-571.
Studer, R. K., et al., “Chrondrocyte Response to Growth Factors is Modulated by p38 Mitogen-Activated protein Kinase Inhibitors,”Arthritis Research Ther.(2004) vol. 6, pp. R56-64.
Wada, Y., et al., “R-130823, a Novel Inhibitor of p38 MAPK, Ameliorates Hyperalgesia and Swelling in Arthritis Models,”Europ. J. Pharmacol.(2005) vol. 506, pp. 285-295.
Wadsworth, S. A., et al., “RWJ 67657, a Potent, Orally Active Inhibitor of p38 Mitogen-Activated Protein Kinase,”J. Pharm. Exp. Therapeutics(1999) vol. 291 (2) pp. 680-687.
Arora Nidhi
Billedeau Roland Joseph
Dewdney Nolan James
Gabriel Tobias
Goldstein David Michael
Coleman Brenda
Hall Robert C.
Moore Susanna
Roche Palo Alto LLC
LandOfFree
Substituted pyrazolo[3,4-d]pyrimadines and methods of using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazolo[3,4-d]pyrimadines and methods of using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazolo[3,4-d]pyrimadines and methods of using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002183